Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy - UNICANCER Accéder directement au contenu
Article Dans Une Revue Frontiers in Oncology Année : 2021

Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy

Résumé

tumor angiogenesis, metastasis and growth following treatment with AM-neutralizing antibodies, AM receptor antagonists, or AM receptor interference. Anti-AM therapy is a promising strategy to be explored in oncology, not only as an anti-angiogenic alternative in the context of acquired resistance to VEGF treatment, but also as a potential antimetastatic approach.

Domaines

Cancer
Fichier principal
Vignette du fichier
Targeting Adrenomedullin in Oncology_ A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy fonc-10-589218 (1).pdf (17 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03105775 , version 1 (11-01-2021)

Licence

Paternité

Identifiants

Citer

Ramiro Vázquez, Maria E Riveiro, Caroline Berenguer-Daize, Anthony O’kane, Julie Gormley, et al.. Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy. Frontiers in Oncology, 2021, 10, ⟨10.3389/fonc.2020.589218⟩. ⟨hal-03105775⟩
165 Consultations
41 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More